2Fried LF,Orchard TJ,Kasiske BL.Effect of lipid reduction on the progression of renal disease; a meta-analysis[J].Kidney Int 2001; 59(1):260-269.
3Kim S L,Han D C,Lee H B.Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangil cells[J].J Am Soc Nephrol 2000;11:80-87.
4Usui H,Shikata K,Matsuda M,et al.HMG-CoA reductase inhibitor meliorates diabetic nephropathy by its pleiotropic effectsin rats[J].J Nephrol Dial Transplant 2003;18(2):265-272.
5Nakamura T,Ushiyama C,Hirokawa K,et al.Effect of cervastatin on urinary albumin excretion and plasma ET-1 concentrationsin type 2diabetes patients with microalbuminuria and dyslipidemia[J].Am J Nephrol 2001;21(60):449-454.
6Struebe G,Hahn A,Iwanciw D,et al.Regulation of connective tissue growth factor (ccn2; ctgf)gene expression in human mesangial cells:modulationby HMG CoA reductase inhibitors(statins)[J].J Clin Pathol:Mol Pathol 2001;54:176-179.
7Danesh FR,Sadeghi MM,Amro N,et al.3-Hydroxy-3 -methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/P21 signaling pathway:Implications for diabetic nephropathy[J].Proc Natl Acad Sci USA 2002;99(12):8301-8305.
8Tsunekawa T,Hayashi T,Kano H,et al.Cerivastatin.ahydroxymethylglutaryl coenzyme a reductase inhibitor,improves endothelial function in elderly diabetic patients within 3 days[J].Circulation 2001; 104(4):376-379.
9Lopez S.Peiretti F,Bonardo B,et al.Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages[J].J Cardiovasc Pharmacol 2001 ;37(6):762-768.
10Miossec P,Zkhiri F,Paries J,et al.Effect of pravsstatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabet ic Patients[J].Diabet Med 1999;16(5):424 -430.
